X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB NOVARTIS UNICHEM LAB/
NOVARTIS
 
P/E (TTM) x -62.3 318.8 - View Chart
P/BV x 0.7 35.3 2.0% View Chart
Dividend Yield % 2.4 1.3 187.5%  

Financials

 UNICHEM LAB   NOVARTIS
EQUITY SHARE DATA
    UNICHEM LAB
Mar-18
NOVARTIS
Mar-18
UNICHEM LAB/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs382758 50.4%   
Low Rs234579 40.4%   
Sales per share (Unadj.) Rs116.3228.4 50.9%  
Earnings per share (Unadj.) Rs-18.931.7 -59.6%  
Cash flow per share (Unadj.) Rs-11.732.8 -35.8%  
Dividends per share (Unadj.) Rs5.0010.00 50.0%  
Dividend yield (eoy) %1.61.5 108.5%  
Book value per share (Unadj.) Rs381.0297.1 128.2%  
Shares outstanding (eoy) m70.3424.69 284.9%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x2.62.9 90.5%   
Avg P/E ratio x-16.321.1 -77.3%  
P/CF ratio (eoy) x-26.220.4 -128.6%  
Price / Book Value ratio x0.82.2 35.9%  
Dividend payout %-26.431.5 -83.9%   
Avg Mkt Cap Rs m21,66816,505 131.3%   
No. of employees `0002.30.7 341.3%   
Total wages/salary Rs m2,0061,445 138.8%   
Avg. sales/employee Rs Th3,587.88,441.3 42.5%   
Avg. wages/employee Rs Th880.02,163.6 40.7%   
Avg. net profit/employee Rs Th-583.71,173.1 -49.8%   
INCOME DATA
Net Sales Rs m8,1805,639 145.1%  
Other income Rs m6101,718 35.5%   
Total revenues Rs m8,7907,357 119.5%   
Gross profit Rs m-1,320-63 2,112.3%  
Depreciation Rs m50525 1,996.4%   
Interest Rs m8055 144.8%   
Profit before tax Rs m-1,2951,575 -82.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m33792 4.2%   
Profit after tax Rs m-1,331784 -169.8%  
Gross profit margin %-16.1-1.1 1,456.1%  
Effective tax rate %-2.650.3 -5.1%   
Net profit margin %-16.313.9 -117.1%  
BALANCE SHEET DATA
Current assets Rs m23,3189,522 244.9%   
Current liabilities Rs m4,6353,296 140.6%   
Net working cap to sales %228.4110.4 206.9%  
Current ratio x5.02.9 174.1%  
Inventory Days Days12237 332.6%  
Debtors Days Days12128 427.4%  
Net fixed assets Rs m8,16346 17,746.1%   
Share capital Rs m141123 114.0%   
"Free" reserves Rs m26,6607,213 369.6%   
Net worth Rs m26,8017,336 365.3%   
Long term debt Rs m30-   
Total assets Rs m31,89011,105 287.2%  
Interest coverage x-15.229.5 -51.5%   
Debt to equity ratio x00-  
Sales to assets ratio x0.30.5 50.5%   
Return on assets %-3.97.6 -51.9%  
Return on equity %-5.010.7 -46.5%  
Return on capital %-4.522.2 -20.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,35661 7,188.8%   
Fx outflow Rs m03,630 0.0%   
Net fx Rs m4,356-3,570 -122.0%   
CASH FLOW
From Operations Rs m-1,1231,610 -69.8%  
From Investments Rs m16,487687 2,399.8%  
From Financial Activity Rs m-8,811-2,677 329.2%  
Net Cashflow Rs m6,552-380 -1,726.0%  

Share Holding

Indian Promoters % 50.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 15.1 2.0 755.0%  
FIIs % 3.0 1.6 187.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 21.5 147.4%  
Shareholders   20,176 41,647 48.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   IPCA LABS  GSK PHARMA  PANACEA BIOTECH  MERCK LTD  SANOFI INDIA  

Compare UNICHEM LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Realty & Auto Stocks Top Losers(09:30 am)

Asian shares eased in holiday-thinned trading on Monday and the safe haven yen gained as China canceled upcoming tariff talks with the United States.

Related Views on News

UNICHEM LAB Announces Quarterly Results (1QFY19); Net Profit Down 1479.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, UNICHEM LAB has posted a net profit of Rs 207 m (down 1479.6% YoY). Sales on the other hand came in at Rs 2 bn (down 35.9% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Sep 24, 2018 12:45 PM

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB 5-YR ANALYSIS

COMPARE UNICHEM LAB WITH

MARKET STATS